Overview

Inflammatory diseases – including psoriasis, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis and atherosclerosis – can be devastating and often life-threatening, are widespread and are currently not adequately treated or prevented.

VBL Therapeutics is committed to developing and bringing to patients first-in-class treatments for inflammatory diseases that will transform the way these conditions are treated and bring new hope to those facing these diseases.

Psoriasis Market

According to GlobalData, the psoriasis market was worth $2.4 billion in 2008 and expected to exceed $4 billion in 2015. The biologics created over $1 billion sales in 2008 across the seven major markets, contributing 55 percent of the psoriasis market (DATAMONITOR). While advances have been made in the treatment of psoriasis over the last decade with the advent of biologics, many of these treatments require subcutaneous injection by patients, often have serious side effects (e.g., infections, malignancies, progressive multifocal leukoencephalopathy), and are cost prohibitive for a number of patients and payers. There remains a significant, unmet need for a safe, effective, oral treatment option for psoriasis.